WHO/Health Canada meeting on regulatory considerations for evaluation and licensing of new meningococcal Group B vaccines, Ottawa, Canada, 3-4 October 2011

Biologicals

Volumn 40, Issue 6, 2012, Pages 507-516

  Feavers, Ian ^a   Griffiths, Elwyn ^b   Baca Estrada, Maria ^b   Knezevic, Ivana ^c   Zhou, TieQun ^c  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^b HEALTH CANADA   (Canada)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Meningococcal B vaccine; Regulatory consideration; Standardization

Indexed keywords

ANTIBODY; BEXSERO; MENINGOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; UNCLASSIFIED DRUG;

ANTIGENICITY; ASSAY; BACTERIAL STRAIN; CONFERENCE PAPER; CONSENSUS; DRUG APPROVAL; DRUG CONTROL; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG SCREENING; ENDEMIC DISEASE; EPIDEMIC; HEALTH CANADA; HEALTH CARE ORGANIZATION; HUMAN; IMMUNOGENICITY; IN VITRO ASSAY; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL; REPEATED DRUG DOSE; SERUM BACTERICIDAL ANTIBODY ASSAY; STANDARDIZATION; WORLD HEALTH ORGANIZATION;

LICENSURE; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; MOLECULAR EPIDEMIOLOGY; ONTARIO; WORLD HEALTH; WORLD HEALTH ORGANIZATION;

NEISSERIA MENINGITIDIS;

EID: 84868372677     PISSN: 10451056     EISSN: 10958320     Source Type: Journal    
DOI: 10.1016/j.biologicals.2012.09.008     Document Type: Conference Paper

References (17)

1. Maiden M.C.J., Caugant D.A. The population biology of Neisseria meningitidis: implications for meningococcal disease, epidemiology and control. Handbook of meningococcal disease 2006, 17-35. Wiley-VCH, Weinheim. M. Frosch, M.C.J. Maiden (Eds.).
2. Finne J., Leinonen M., Makela P.H. Antigenic similarities between brain components and bacteria causing meningitis: implications for vaccine development and pathogenesis. Lancet 1983, 322:355-357.
3. Caugant D.A., Maiden M.C. Meningococcal carriage and disease-population biology and evolution. Vaccine 2009, 27(Suppl. 2):B64-B70.
4. Dull P.M., McIntosh E.D. Meningococcal vaccine development - from glycoconjugates against MenACWY to proteins against MenB - potential for broad protection against meningococcal disease. Vaccine 2012, 30(Suppl. 2):B18-B25.
5. Fletcher L.D., Bernfield L., Barniak V., Farley J.E., Howell A., Knauf M., et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 2004, 72(4):2088-2100.
6. Murphy E., Andrew L., Lee K.L., Dilts D.A., Nunez L., Fink P.S., et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis 2009, 200:379-389.
7. Borrow R., Carlone G.M., Rosenstein N., Blake M., Feavers I., Martin D., et al. Neisseria meningitidis group B correlates of protection and assay standardization-international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine 2006, 24(24):5093-5107.
8. Racloz V.N., Luiz S.J. The elusive meningococcal meningitis serogroup: a systematic review of serogroup B epidemiology. BMC Infect Dis 2010, 10:175.
9. Sierra G.V., Campa H.C., Varcacel N.M., Garcia I.L., Izquierdo P.L., Sotolongo P.F., et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 1991, 14(2):195-207.
10. Chiou C.S., Liao J.C., Liao T.L., Li C.C., Chou C.Y., Chang H.L., et al. Molecular epidemiology and emergence of worldwide epidemic clones of Neisseria meningitidis in Taiwan. BMC Infect Dis 2006, 6:25.
11. Loring B.J., Turner N., Petousis-Harris H. MeNZB vaccine and epidemic control: when do you stop vaccinating?. Vaccine 2008, 26(47):5899-5904.
12. von G.A., du P.M., Cohen C., Prentice E., Schrag S., de G.L., et al. Emergence of endemic serogroup W135 meningococcal disease associated with a high mortality rate in South Africa. Clin Infect Dis 2008, 46(3):377-386.
13. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human immunity to the meningococcus. I. the role of Humoral antibodies. J Exp Med 1969, 129:1307-1326.
14. Ross S.C., Rosenthal P.J., Berberich H.M., Densen P. Killing of Neisseria meningitidis by human neutrophils: implications for normal and complement-deficient individuals. J Infect Dis 1987, 155:1266-1275.
15. Zollinger W.D., Moran E.E., Devi S.J., Frasch C.E. Bactericidal antibody responses of juvenile rhesus monkeys immunized with group B Neisseria meningitidis capsular polysaccharide-protein conjugate vaccines. Infect Immun 1997, 65:1053-1060.
16. Maslanka S.E., Gheesling L.L., Libutti D.E., Donaldson K.B., Harakeh H.S., Dykes J.K., et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The multilaboratory study group. Clin Diagn Lab Immunol 1997, 4:156-167.
17. Lemos A.P., Brandão A.P., Gorla M.C., Paiva M.V., Simonsen V., Melles C.E. Phenotypic characterization of Neisseria meningitidis strains isolated from invasive diseases in Brazil from 1999 to 2001. J Med Microbiol 2006, 55:751-757.